

CITATION REPORT

List of articles citing

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

DOI: 10.1016/s0140-6736(16)32409-6
Lancet, The, 2017, 389, 1011-1024.

Source: <https://exaly.com/paper-pdf/65996356/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1281	Clinical Decision-Making in Pancreatic Cancer. 2016 , 1-32		
1280	Pancreatic cancer: are more chemotherapy and surgery needed?. <i>Lancet, The</i> , 2017 , 389, 985-986	40	34
1279	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. 2017 , 2, 337-346		20
1278	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. 2017 , 18, 486-499		47
1277	Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. 2017 , 22, 690-701		15
1276	Pancreatic cancer: Addition of capecitabine prolongs overall survival. 2017 , 14, 198		1
1275	Oncolytic viral therapy for pancreatic cancer. 2017 , 116, 94-103		24
1274	Beyond ESPAC-4: better surgery and systemic therapy. <i>Lancet, The</i> , 2017 , 389, 1517-1518	40	4
1273	Targeting metabolism in pancreatic cancer. 2017 , 18, 699-700		8
1272	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. 2017 , 79, 41-49		36
1271	Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany and review of the literature. 2017 , 55, 657-666		3
1270	Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. 2017 , 123, 3816-3824		30
1269	Scientific Surgery June 2017 BJS. 2017 , 104, 946-946		
1268	Current and future therapies for advanced pancreatic cancer. 2017 , 116, 25-34		75
1267	Minimally invasive pancreatic cancer surgery: What is the current evidence?. 2017 , 34, 125		9
1266	The pancreatic cancer microenvironment: A true double agent. 2017 , 116, 7-15		44
1265	Active Systemic Treatment of Pancreatic Cancer. 2017 , 15, 723-725		3

1264	Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. 2017 , 90, 20170165	9
1263	Pancreatic cancer: moving forward, step by step. 2017 , 2, 315-316	1
1262	Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review. 2017 , 48, 121-128	28
1261	Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. 2017 , 266, 787-796	55
1260	Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. 2017 , 117, 1874-1882	46
1259	Clinical Trials in Pancreatic Cancer: A Long Slog. 2017 , 22, 1424-1426	3
1258	Current Standards of Chemotherapy for Pancreatic Cancer. 2017 , 39, 2125-2134	45
1257	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. 2017 , 17, 951-964	1
1256	Improving post-surgical management of resected pancreatic cancer. <i>Lancet, The</i> , 2017 , 390, 847-848	40 6
1255	Trends in Neoadjuvant Approaches in Pancreatic Cancer. 2017 , 15, 1070-1077	21
1254	Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?. 2017 , 21, 1793-1803	18
1253	How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?. 2017 , 8, 407-412	7
1252	Improving outcomes in patients with resectable pancreatic cancer. 2017 , 104, 1421-1423	8
1251	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 , 15, 1028-1061	544
1250	Pancreatic cancer screening: Still a delusion?. 2017 , 17, 754-765	14
1249	Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. 2017 , 123, 4158-4167	50
1248	Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. 2017 , 19, 859-867	40
1247	Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. 2017 , 19, 944-950	4

1246	Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. 2017 , 19, 1193-1198	3
1245	Randomized Clinical Trials in Pancreatic Cancer. 2017 , 26, 767-790	7
1244	Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. 2017 , 1868, 394-403	36
1243	Clinical Management: Resectable Disease. 2017 , 23, 343-349	8
1242	Biliary Obstruction: Endoscopic Approaches. 2017 , 34, 369-375	6
1241	Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices. 2017 , 40, 784-788	1
1240	The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. 2017 , 18, 73	4
1239	Gastrointestinal Cancers: Timing Is Everything. 2017 , 99, 1051-1058	
1238	Gastrointestinal Tract Malignancies: Obstacles and Advancements. 2017 , 39, 2122-2124	0
1237	Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. 2017 , 24, 2770-2776	17
1236	Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC). 2017 , 43, 1704-1710	21
1235	Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. 2017 , 46, 994-1002	14
1234	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. 2017 , 43, 1711-1717	22
1233	[R1 resection for pancreatic carcinoma]. 2017 , 88, 764-770	2
1232	Adjuvant treatment for pancreatic ductal carcinoma. 2017 , 19, 1199-1204	7
1231	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. 2017 , 18,	15
1230	Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience. 2017 , 103, 577-582	1
1229	Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. 2017 , 5,	49

1228	Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. 2017 , 17, 94	61
1227	Chemotherapy and tumor microenvironment of pancreatic cancer. 2017 , 17, 68	58
1226	Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. 2017 , 16, 169	153
1225	Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. 2017 , 15, 183	78
1224	Anaplastic Pancreatic Carcinoma Arising Within a Mucinous Cystic Neoplasm of the Pancreas: A Case Report and a Brief Review of the Literature. 2017 , 3, 40-45	3
1223	CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. 2017 , 35, 3330-3337	143
1222	Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment. 2018 , 194, 627-637	4
1221	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. 2018 , 118, 947-954	23
1220	The challenge of treating older patients with pancreaticobiliary malignancies. 2018 , 42, 59-72	7
1219	The Dutch Pancreas Biobank Within the Parelshoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases. 2018 , 47, 495-501	6
1218	Quality of Life in Patients With Pancreatic Cancer and Their Caregivers: A Systematic Review. 2018 , 47, 368-375	34
1217	Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. 2018 , 1869, 248-255	16
1216	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. 2018 , 42, 8-11	
1215	A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. 2018 , 20, 379-384	32
1214	A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer. 2018 , 25, 1889-1895	7
1213	Poorly differentiated ductal adenocarcinoma of the pancreas with rapid progression in a young man. 2018 , 11, 417-423	
1212	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. 2018 , 3, 413-423	98
1211	Shifting the treatment model for resectable pancreatic cancer. 2018 , 3, 375-376	1

1210	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. 2018 , 23, 704-711	11
1209	Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. 2018 , 3, e000282	15
1208	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. 2018 , 268, 1-8	98
1207	A look at the progress of treating pancreatic cancer over the past 20 years. 2018 , 18, 295-304	15
1206	Patient-derived organoid models help define personalized management of gastrointestinal cancer. 2018 , 105, e48-e60	71
1205	Defining the molecular pathology of pancreatic body and tail adenocarcinoma. 2018 , 105, e183-e191	64
1204	Pancreaticoduodenectomy for periampullary tumours: a review article based on Surveillance, End Results and Epidemiology (SEER) database. 2018 , 20, 1153-1160	18
1203	Adjuvant Chemotherapy in Pancreatic Cancer. 2018 , 847-855	1
1202	Adjuvant and Palliative Chemotherapy of Periampullary Cancers. 2018 , 1089-1096	
1201	Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?. 2018 , 25, 1052-1060	4
1200	[Early stage pancreatic cancer]. 2018 , 89, 257-265	1
1199	Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy. 2018 , 5, 27-31	2
1198	CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. 2018 , 24, 1415-1425	52
1197	Medical oncology and pancreatic cancer: what the radiologist needs to know. 2018 , 43, 383-392	1
1196	Drug development and clinical trial design in pancreatobiliary malignancies. 2018 , 42, 73-94	4
1195	Pancreatic cancer in 2017: Rebooting pancreatic cancer knowledge and treatment options. 2018 , 15, 76-78	15
1194	Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. 2018 , 2, 52-61	17
1193	Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. 2018 , 105, 946-958	220

1192	Therapeutic developments in pancreatic cancer: current and future perspectives. 2018 , 15, 333-348	423
1191	Clinical Decision-Making in Pancreatic Cancer. 2018 , 601-632	
1190	Venous Resection in Pancreatic Cancer Surgery. 2018 , 941-965	
1189	Adjuvant Chemotherapy in Pancreatic Cancer. 2018 , 1039-1071	
1188	Borderline Resectable Pancreatic Cancer. 2018 , 1001-1020	
1187	Circulating Tumor Cells. 2018 , 1325-1360	1
1186	Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma. 2018 , 1401-1434	
1185	Tumor manipulation during pancreatic resection for pancreatic cancer induces dissemination of tumor cells into the peritoneal cavity: a systematic review. 2018 , 20, 289-296	3
1184	Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. 2018 , 25, 1440-1447	49
1183	Current Concepts in the Treatment of Resectable Pancreatic Cancer. 2018 , 20, 39	9
1182	Management of Borderline Resectable Pancreatic Cancer. 2018 , 100, 1155-1174	20
1181	Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01). 2018 , 93, 79-88	10
1180	A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. 2018 , 163, 1280-1294	15
1179	Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. 2018 , 14, 947-962	4
1178	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. 2018 , 118, 1084-1088	5
1177	Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. 2018 , 49, 429-436	4
1176	Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. 2018 , 117, 354-362	19
1175	AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers. 2018 , 51,	47

1174	An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). 2018 , 94, 39-46	10
1173	Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. 2018 , 94, 19-24	18
1172	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. 2018 , 34, 969-979	27
1171	Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. 2018 , 22, 214-225	17
1170	Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. 2018 , 44, 24-30	12
1169	Timing of Pancreatic Resection and Patient Outcomes: Is There a Difference?. 2018 , 98, 57-71	8
1168	Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?. 2018 , 98, 95-111	18
1167	Locally advanced pancreatic cancer: An emerging entity. 2018 , 42, 12-25	9
1166	T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival. 2018 , 25, 475-481	6
1165	Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. 2018 , 22, 695-702	21
1164	Technical aspects of modern radiation therapy for pancreatic adenocarcinoma: field design, motion management, dosing, and concurrent therapy. 2018 , 1, 21-21	1
1163	Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. 2018 , 1,	5
1162	Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. 2018 , 9, 1027-1036	4
1161	Adjuvant chemotherapy with gemcitabine plus erlotinib gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005. 2018 , 7, 399-402	
1160	Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. 2018 , 7, 406-408	0
1159	Neoadjuvant Treatment for Nonmetastatic Pancreatic Cancer. 2018 ,	1
1158	Pancreatic Cancer, Leptin, and Chemoresistance: Current Challenges. 2018 ,	3
1157	Stellungnahme zur adjuvanten Therapie des resezierten Pankreaskarzinoms. 2018 , 33, 267-268	2

1156	Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA)-a difficult question to answer. 2018 , 2,	0
1155	Identification of hub genes with diagnostic values in pancreatic cancer by bioinformatics analyses and supervised learning methods. 2018 , 16, 223	18
1154	Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. 2018 , 10,	7
1153	New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer. 2018 , 13, 691-704	5
1152	Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. 2018 , 403, 917-932	41
1151	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. 2018 , 18, 1298	44
1150	Locally advanced pancreatic cancer successfully treated with high-dose helical tomotherapy. 2018 , 7, 152-155	2
1149	First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report. 2018 , 18, 1243	1
1148	A Glimmer of Hope for Pancreatic Cancer. 2018 , 379, 2463-2464	26
1147	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. 2018 , 379, 2395-2406	1047
1146	Pankreaskarzinom - neue Konzepte?. 2018 , 13, 450-454	
1145	A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model. 2018 , 11, 8655-8672	7
1144	Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. 2018 , 16, 1468-1475	7
1143	Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. 2018 , 10, 1109-1125	6
1142	Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. 2018 , 24, 4846-4861	559
1141	High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm. 2018 , 53, 1597-1603	6
1140	The Management of Older Adults with Pancreatic Adenocarcinoma. 2018 , 3,	2
1139	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. 2018 , 57, 1655-1662	38

1138	The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology. 2018 , 35, 151	7
1137	Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. 2018 , 41, 590-594	7
1136	Chemotherapy for pancreatic cancer: the rise of multidrug regimens. 2018 , 3, 659-660	2
1135	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. 2018 , 25, 4027-4034	10
1134	[mFOLFIRINOX for adjuvant therapy of pancreatic cancer]. 2018 , 89, 1007	
1133	[Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma]. 2018 , 39, 221-224	
1132	Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. 2018 , 18, 1034	6
1131	Radiation Therapy in Pancreatic Cancer. 2018 , 1-11	
1130	Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. 2018 , 18, 962-970	41
1129	Currently available first-line drug therapies for treating pancreatic cancer. 2018 , 19, 1927-1940	3
1128	Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. 2018 , 10, 4065-4072	6
1127	Fluorescent-guided surgery for sentinel lymph node detection in gastric cancer and carcinoembryonic antigen targeted fluorescent-guided surgery in colorectal and pancreatic cancer. 2018 , 118, 315-323	19
1126	Personalisierte Therapie von gastrointestinalen Malignomen. 2018 , 21, 37-43	
1125	Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. 2018 , 11, 1307-1322 ⁹	
1124	Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). 2018 , 82, 935-943	6
1123	Focus on pancreatic cancer. 2018 , 50, 1272-1273	
1122	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). 2018 , 50, 1257-1271	65
1121	Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation?. 2018 , 47, e50-e52	4

1120	A Copper-Paclitaxel crystal; a medicinally active drug delivery platform. 2018 , 28, 3409-3417	3
1119	Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. 2018 , 12, 475-480	13
1118	Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. 2018 , 25, 3492-3501	2
1117	Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. 2018 , 50, 979-990	20
1116	Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer. 2018 , 164, 1168-1177	10
1115	FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. 2018 , 25, 1896-1903	64
1114	Pancreatic Cancer. 2018 , 441-458	
1113	Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. 2018 , 41, 1185-1192	7
1112	Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. 2018 , 18, 585-591	5
1111	The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. 2018 , 48, 952-962	6
1110	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. 2018 , 35, 100	8
1109	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. 2018 , 8, 1112-1129	394
1108	Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. 2018 , 57, 1185-1191	10
1107	Do patients with pancreatic body or tail cancer benefit from adjuvant therapy? A cohort study. 2018 , 27, 245-250	5
1106	Immunotherapy for pancreatic cancer: Barriers and breakthroughs. 2018 , 2, 274-281	87
1105	[Pancreatic Cancer in the Year 2018 - Room for Precision Medicine?]. 2018 , 143, 1109-1112	
1104	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. 2018 , 23, 1848-1872	7
1103	Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). 2018 , 18, 762	53

1102	Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. 2018 , 18, 671-677	13
1101	Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. 2018 , 27, 619-624	2
1100	[Maintenance strategies for advanced pancreatic cancer: Rationale and issues]. 2018 , 105, 739-741	2
1099	Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. 2017 , 10,	68
1098	Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. 2018 , 6,	2
1097	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. 2018 , 10,	14
1096	Contemporary Management of Localized Resectable Pancreatic Cancer. 2018 , 10,	35
1095	Role of Gene Therapy in Pancreatic Cancer-A Review. 2018 , 10,	14
1094	[Pancreatic ductal adenocarcinoma]. 2018 , 59, 805-822	8
1093	The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. 2018 , 17, 95	41
1092	Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. 2018 , 182, 816-829	13
1091	Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. 2018 , 11, 14	22
1090	Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. 2018 , 105, 1171-1181	47
1089	[Role of radiation therapy in the management of pancreatic cancer]. 2018 , 22, 552-557	
1088	Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma. 2018 , 8, 282	10
1087	Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. 2018 , 22, 1804-1810	19
1086	An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. 2018 , 9, 373-381	7
1085	Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients. 2018 , 164, 432-442	16

1084	Sequence therapy in metastatic pancreatic cancer. 2018 , 56, 578-582	1
1083	Management of delayed stenosis of pancreatico-enteric anastomosis following pancreatoduodenectomy. 2019 , 156, 30-36	4
1082	A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy. 2019 , 21, 204-211	2
1081	Correlates of Refusal of Surgery in the Treatment of Non-metastatic Pancreatic Adenocarcinoma. 2019 , 26, 98-108	21
1080	Neue Standards in der adjuvanten Therapie des Pankreaskarzinoms?!. 2019 , 14, 126-128	
1079	Duktales Adenokarzinom des Pankreas. 2019 , 14, 131-148	
1078	Gastrointestinal Cancers: Fine-Tuning the Management of Rectal, Esophageal, and Pancreas Cancers. 2019 , 105, 1-10	3
1077	Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. 2019 , 17, 2029-2041	21
1076	Gastroenterology For General Surgeons. 2019 ,	1
1075	Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. 2019 , 154, 943-951	41
1074	Evaluation of the clinical and economic impact of delays to surgery in patients with periampullary cancer. 2019 , 3, 476-484	3
1073	Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis. 2019 , 8, 5881-5890	3
1072	ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials. 2019 , 30, 1410-1413	o
1071	Acute Pancreatitis, Chronic Pancreatitis and Pancreatic Neoplasms. 2019 , 103-117	
1070	Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. 2019 , 26, 4489-4497	11
1069	Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer. 2019 , 2, e199126	24
1068	Aktuelle Diagnostik und Therapiekonzepte für das Pankreaskarzinom. 2019 , 15, 135-147	
1067	Diagnostik und Therapie des Pankreaskarzinoms. 2019 , 48, 242-249	

1066	Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. 2019 , 101, 453-462	17
1065	Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. 2019 , 154, e193019	12
1064	Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. 2019 , 121, 264-270	8
1063	A Prospective Clinical Trial to Determine the Effect of Intraoperative Ultrasound on Surgical Strategy and Resection Outcome in Patients with Pancreatic Cancer. 2019 , 45, 2019-2026	2
1062	Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. 2019 , 30, 1472-1478	71
1061	Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival. 2019 , 26, 4108-4116	42
1060	Ist nicht obligat: histologische Sicherung vor neoadjuvanter Therapie des Pankreaskarzinoms. 2019 , 25, 658-660	
1059	Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: The Good, the Bad and the Ugly Scenario. 2019 , 11,	3
1058	Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. 2019 , 212, 67-79	4
1057	Local radicality and survival outcome of pancreatic cancer surgery. 2019 , 3, 464-475	21
1056	Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. 2019 , 9,	3
1055	The Spectrum of Pulmonary Toxicity in Pancreatic Cancer Patients Receiving Gemcitabine Combination Chemotherapy. 2019 , 12, 506-512	3
1054	Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials. 2019 , 98, e15761	0
1053	Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. 2019 , 8,	5
1052	Management of Localized Pancreatic Cancer. 2019 ,	1
1051	Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. 2019 , 14, 114	20
1050	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. 2019 , 53, 253-269	1
1049	State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?. 2019 , 39, 3405-3412	16

1048 [New milestone in adjuvant therapy for pancreatic cancer]. **2019**, 60, 881-884

1047 Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit?. **2019**, 9, 1060

1046 Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. **2019**, 11,

7

1045 Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. **2019**, 31, 16-21

22

1044 An update on treatment options for pancreatic adenocarcinoma. **2019**, 11, 1758835919875568

73

1043 Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. **2019**, 2019, 7135437

3

1042 Impact of different surgical procedures on survival outcomes of patients with adenocarcinoma of pancreatic neck. **2019**, 14, e0217427

1

1041 Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. **2019**, 8, 7705-7719

6

1040 The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. **2019**, 120, 1053-1054

1039 Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. **2019**, 9, 1085

26

1038 Evolving Treatment Paradigms for Pancreatic Cancer. **2019**, 35, 362-372

3

1037 Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. **2019**, 8,

12

1036 Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects. **2019**, 9, 15471

5

1035 Conversion Surgery for Advanced Pancreatic Cancer. **2019**, 8,

10

1034 Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. **2019**, 26, e665-e681

1

1033 Pancreas Cancer. **2019**, 111-117

1032 Aktuelle Entwicklungen zur neoadjuvanten und adjuvanten Therapie des Pankreaskarzinoms. **2019**, 22, 260-267

1031 Systemische Therapie des Pankreaskarzinoms Was hat sich viel getan. **2019**, 22, 22-26

- 1030 Gezielte Ernährung beim Pankreaskarzinom läuft keinen Fall vernachlässigen!. **2019**, 22, 31-36
- 1029 Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. **2019**, 39, 5781-5787 1
- 1028 Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. **2019**, 120, 1055
- 1027 Maligne Tumoren der Bauchspeicheldrüse. **2019**, 16, 57-71
- 1026 FOLFIRINOX nach Resektion von Pankreaskarzinomen setzt neue Maßstäbe. **2019**, 22, 33-34
- 1025 Are /ENT1, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?. **2019**, 11, 4
- 1024 Meta-analysis of recurrence pattern after resection for pancreatic cancer. **2019**, 106, 1590-1601 59
- 1023 The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study. **2019**, 33, 148-153 12
- 1022 Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. **2019**, 13, 430 6
- 1021 Results of portosystemic shunts during extended pancreatic resections. **2019**, 404, 959-966 8
- 1020 Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. **2019**, 36, 83 3
- 1019 FOLFIRINOX beim duktalem Adenokarzinom des Pankreas. **2019**, 25, 726-727
- 1018 Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. **2019**, 154, 1038-1048 63
- 1017 Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma. **2019**, 154, e193348 13
- 1016 Pancreatic Ductal Adenocarcinoma-ESPAC4r It's Back?. **2019**, 154, 1048 1
- 1015 Outcomes in patients ≥80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. **2019**, 36, 85 4
- 1014 [Relief of Obstruction in the Management of Pancreatic Cancer]. **2019**, 74, 69-80
- 1013 Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. **2019**, 7, 255 81

1012	NF- κ B Dependent Chemokine Signaling in Pancreatic Cancer. 2019 , 11,	15
1011	Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients. 2019 , 18, 1534735419878505	16
1010	The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. 2019 , 10, 462-473	4
1009	Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis. 2019 , 72, 59-68	14
1008	Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. 2019 , 20,	31
1007	Capecitabine for the treatment of pancreatic cancer. 2019 , 20, 399-409	15
1006	Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?. 2019 , 135, 95-102	5
1005	First results from the Swedish National Pancreatic and Periapillary Cancer Registry. 2019 , 21, 34-42	23
1004	CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. 2019 , 19, 302-306	8
1003	A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). 2019 , 24, 589-e160	17
1002	Comparison of end-to-end anastomosis and interposition graft during pancreatoduodenectomy with portal vein reconstruction for pancreatic ductal adenocarcinoma. 2019 , 404, 191-201	14
1001	Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer. 2019 , 8, 939-952	7
1000	Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. 2019 , 40, 394-405	16
999	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. 2019 , 11,	12
998	Pancreatic cancer in young adults: changes, challenges, and solutions. 2019 , 12, 3387-3400	9
997	Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis synergistic upregulation of ALAS1 expression. 2019 , 9, 937-951	13
996	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. 2019 , 11, 1758835919841233 ²¹	
995	Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer. 2019 , 4, 32	13

994	Overexpression of PODXL/ITGB1 and BCL7B/ITGB1 accurately predicts unfavorable prognosis compared to the TNM staging system in postoperative pancreatic cancer patients. 2019 , 14, e0217920	6
993	Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. 2019 , 30, 1395-1397 ¹⁰	
992	Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. 2019 , 25, 2430-2441	17
991	Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. 2019 , 15, 1805-1810	
990	Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation. 2019 , 11,	22
989	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. 2019 , 25, 4973-4984	55
988	Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. 2019 , 10, 259-269	20
987	Adjuvant treatment for pancreatic cancer. 2019 , 4, 27	18
986	Pancreatic cancer. 2019 , 47, 433-439	3
985	Nowadays pancreatic cancer prognosis. 2019 , 152, 395-396	
984	Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer. 2019 , 39, 3177-3183	5
983	FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas. 2019 , 15, 1947-1950	
982	Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. 2019 , 8,	3
981	Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. 2019 , 8,	10
980	Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. 2019 , 11,	10
979	Management of ductal pancreatic cancer. 2019 , 51, 135-138	1
978	Current Status of Immunotherapies for Treating Pancreatic Cancer. 2019 , 21, 60	24
977	HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. 2019 , 44, 403-418	11

976	Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. 2019 , 19, 468	16
975	Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. 2019 , 121, 5-14	79
974	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. 2019 , 111, 782-794	113
973	Principle of Nursing in Oncology. 2019 ,	
972	Evolution of oncosurgical management of pancreatic cancer. 2019 , 51, 165-173	4
971	Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. 2019 , 24, 1281-1294	12
970	Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. 2019 , 12, 603-608	3
969	Pancreatic cancer. 2019 , 37, 319-326	4
968	Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer. 2019 , 19, 416	13
967	Cavitation-induced release of liposomal chemotherapy in orthotopic murine pancreatic cancer models: A feasibility study. 2019 , 43, 669-681	5
966	Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. 2019 , 51, 153-164	2
965	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. 2019 , 156, 2242-2253. ¹¹⁷	117
964	Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. 2019 , 19, 252	39
963	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. 2019 , 20, 663-673	392
962	Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. 2019 , 21, 1203-1210	15
961	Diagnostic strategy with a solid pancreatic mass. 2019 , 48, e125-e145	11
960	Pancreatic cancer □What's next?. 2019 , 48, e187-e197	3
959	Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells. 2019 , 20, 855-865	7

958	FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. 2019 , 380, 1187-1188	7
957	Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. 2019 , 106, 756-764	26
956	Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. 2019 , 119, 932-940	8
955	Why is pancreatic cancer so deadly? The pathologist's view. 2019 , 248, 131-141	39
954	Organoid models for translational pancreatic cancer research. 2019 , 54, 7-11	31
953	Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. 2019 , 14, e0212805	6
952	Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma. 2019 , 17, 29	21
951	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. 2019 , 11,	17
950	Pancreatic cancer surgical management. 2019 , 48, e147-e158	11
949	Effects of duration of initial treatment on postoperative complications in pancreatic cancer. 2019 , 26, 235-241	4
948	Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma. 2019 , 3, 85-94	4
947	[FOLFIRINOX after resection of pancreatic cancer sets new standards-systemic therapy providing an impulse for local treatment in resectable pancreatic cancer]. 2019 , 195, 570-572	
946	"Laparoscopic Para-Aortic Lymph Node Sampling" First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. 2019 , 29, 900-904	4
945	Exosomes from Pancreatic Juice: A Step Closer to the Holy Grail?. 2019 , 26, 1961-1962	
944	A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. 2019 , 9, 1280-1287	28
943	Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. 2019 , 21, 998-1008	11
942	Chemotherapy for pancreatic cancer. 2019 , 48, e159-e174	65
941	Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. 2019 , 49, 295-299	25

940	Immunotherapy of pancreatic cancer. 2019 , 164, 189-216	23
939	Propensity score-matched analysis of early outcomes after laparoscopic-assisted versus open pancreaticoduodenectomy. 2019 , 89, E190-E194	14
938	Radical pancreatic cancer surgery-with arterial resection. 2019 , 4, 8	23
937	Neo-adjuvant therapy for pancreatic cancer: hope for the future. 2019 , 13, 579-589	3
936	Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. 2019 , 11,	35
935	Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming. 2019 , 38, 132	30
934	Aktuelle Entwicklungen zur neoadjuvanten und adjuvanten Therapie des Pankreaskarzinoms. 2019 , 25, 669-677	
933	Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score. 2019 , 7, 358-368	7
932	Factors affecting healing time of postoperative pancreatic fistula in patients undergoing pancreaticoduodenectomy. 2019 , 10, 435-440	7
931	Integrating radiation oncology into the management of pancreatic cancer. 2019 , 51, 139-145	0
930	Radical antegrade modular pancreateosplenectomy for all pancreatic body and tail tumors: rationale and results. 2019 , 404, 183-190	8
929	The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma. 2019 , 239, 60-66	26
928	An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer. 2019 , 10, 584-590	1
927	Nowadays pancreatic cancer prognosis. 2019 , 152, 395-396	
926	Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. 2019 , 9, 1489	3
925	Dual-functional melanin-based nanoliposomes for combined chemotherapy and photothermal therapy of pancreatic cancer.. 2019 , 9, 3012-3019	6
924	Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. 2019 , 165, 1151-1160	19
923	Progressive Resistance Training to Impact Physical Fitness and Body Weight in Pancreatic Cancer Patients: A Randomized Controlled Trial. 2019 , 48, 257-266	36

922	Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. 2019 , 48, 216-222	34
921	Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins. 2019 , 4, 294-301	4
920	Impact of Immunotherapy after Resection of Pancreatic Cancer. 2019 , 229, 19-27.e1	7
919	High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. 2019 , 40, 947-955	14
918	[mFOLFIRINOX for adjuvant therapy of pancreatic cancer]. 2019 , 90, 59	
917	Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. 2019 , 106, 342-354	22
916	Advances in the Treatment of Pancreatic Cancer. 2019 ,	1
915	Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. 2019 , 9, e028696	3
914	Experiences and supportive care needs of UK patients with pancreatic cancer: a cross-sectional questionnaire survey. 2019 , 9, e032681	6
913	Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma. 2019 , 2,	0
912	Adenosine in pancreatic cancer: Emerging combination therapies. 2019 , 48, 20-21	2
911	Induction Therapy in Localized Pancreatic Cancer. 2019 , 48, 913-919	3
910	Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery: a single center experience. 2019 , 2, 22-27	5
909	Comment on "Pancreatoduodenectomy: Still an Open Race for a Gold Standard". 2019 , 270, e90	
908	The synergic inhibitory effects of dark tea (<i>Camellia sinensis</i>) extract and p38 inhibition on the growth of pancreatic cancer cells. 2019 , 10, 6557-6569	2
907	PODXL1 promotes metastasis of the pancreatic ductal adenocarcinoma by activating the C5aR/C5a axis from the tumor microenvironment. 2019 , 21, 1121-1132	3
906	Outcomes in patients with pancreatic cancer as a secondary malignancy: a retrospective single-institution study. 2019 , 404, 975-983	1
905	Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome. 2019 , 48, 1086-1091	11

904	Response to Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma" by Niccolo Petrucciani, MD, PhD, FACS, Laura Antolino, MD, Giovanni Moschetta, MD, Giovanni Ramacciato, MD, FACS. 2019 , 270, e130-e131	1
903	Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.. 2019 , 3, 1-10	13
902	Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients. 2019 , 12, 821-828	
901	Prognostic Factors of Acinar Cell Carcinomas: A Study of 44 Patients. 2019 , 48, 1393-1396	5
900	Intraoperative Near-infrared Imaging Can Identify Neoplasms and Aid in Real-time Margin Assessment During Pancreatic Resection. 2019 , 270, 12-20	27
899	Response to Comment on "Bjglom, Ggenur and Bendtsen". 2019 , 270, e89-e90	
898	Predicting Successful Catheter Drainage in Patients With Pancreatic Fistula After Pancreatoduodenectomy. 2019 , 48, 811-816	4
897	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. 2019 , 270, 400-413	66
896	The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. 2019 , 2, 16-21	13
895	Adjuvant and neoadjuvant therapy for pancreatic cancer. 2019 , 2, 100-106	16
894	Adjuvant treatment of pancreatic cancer. 2019 , 31, 346-353	11
893	A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. 2019 , 48, 973-984	4
892	Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model.. 2019 , 9, 41649-41663	9
891	Pankreaskarzinom 2018 ¶reif ffpersonalisierte Therapiekonzepte?. 2019 , 40, 180-183	
890	Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. 2019 , 3, 1-16	7
889	Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline or Mutation.. 2019 , 3, 1-11	8
888	Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines. 2019 , 15, 397-406	7
887	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. 2019 , 54, 194-203	36

886	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. 2019 , 68, 159-171	151
885	Current Approaches to Pancreatic Cancer Screening. 2019 , 189, 22-35	19
884	Venous thromboembolism in patients with cancer undergoing surgical exploration. 2019 , 47, 316-323	8
883	The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. 2019 , 189, 44-57	32
882	Neoadjuvant Treatment for Pancreatic Cancer. 2019 , 46, 19-27	50
881	Systemic treatment of pancreatic cancer revisited. 2019 , 46, 28-38	48
880	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. 2019 , 20, 535-546	12
879	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. 2019 , 24, 945-954	9
878	Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. 2019 , 48, 1-8	9
877	Clinico-pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience. 2019 , 119, 71-78	0
876	Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma. 2019 , 36, 455-461	14
875	Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. 2019 , 145, 445-455	5
874	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. 2019 , 125, 57-67	8
873	The Value of International Collaboration in Pancreatic Cancer Research: EURECCA. 2019 , 26, 705-706	2
872	Selecting chemotherapy for pancreatic cancer: Far away or so close?. 2019 , 46, 39-47	8
871	Late acute pancreatitis after pancreaticoduodenectomy: incidence, outcome, and risk factors. 2019 , 26, 109-116	4
870	Acoustic disruption of tumor endothelium and on-demand drug delivery for cancer chemotherapy. 2019 , 30, 154001	8
869	Optimizing the outcomes of pancreatic cancer surgery. 2019 , 16, 11-26	262

868	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. 2019 , 19, 97-104	29
867	Endoscopic Management of Pancreatic Cancer. 2019 , 28, 147-159	3
866	Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. 2019 , 114, 155-164	6
865	Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study. 2019 , 19, 114-121	45
864	Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. 2019 , 72, 1-6	28
863	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. 2019 , 26, 619-627	6
862	Střiose tardive dānastomose pancrāticodigestive aprē duodēopancrātectomie cēhalique. Quelle prise en charge?. 2019 , 156, 36-43	
861	Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. 2019 , 165, 307-314	14
860	Host Gene Status Influences Tumor Progression and Radiotherapy Response in -Driven Sporadic Pancreatic Cancers. 2019 , 25, 724-734	23
859	SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. 2019 , 12, 15-23	4
858	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. 2019 , 269, 520-529	127
857	Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer. 2019 , 50, 84-90	1
856	Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer. 2019 , 50, 478-484	2
855	Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice. 2020 , 43, 158-164	2
854	Randomized Trial of Pylorus-Preserving vs. Pylorus-Resecting Pancreatoduodenectomy: Long-Term Morbidity and Quality of Life. 2020 , 24, 341-352	4
853	The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms. 2020 , 110, 234-245	6
852	Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. 2020 , 51, 189-195	0
851	Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma. 2020 , 271, 549-558	23

850	Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. 2020 , 101, 519-530	85
849	S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. 2020 , 20, 133-138	4
848	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. 2020 , 4, pkz060	2
847	Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma. 2020 , 51, 506-514	
846	Pancreatic Ductal Adenocarcinoma. 2020 , 55-70	
845	Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution's Experience With 118 Patients. 2020 , 271, 932-940	62
844	Proton beam radiotherapy for pancreas cancer. 2020 , 11, 166-175	6
843	Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer. 2020 , 65, 489-499	16
842	Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. 2020 , 146, 417-428	5
841	Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. 2020 , 32, 5-8	10
840	Clinical impact of additional therapy for residual pancreatic cancer. 2020 , 50, 440-448	0
839	Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. 2020 , 145, 102817	14
838	Isobolographic Analysis Demonstrates the Additive and Synergistic Effects of Gemcitabine Combined with Fucoïdan in Uterine Sarcomas and Carcinosarcoma Cells. 2019 , 12,	3
837	Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. 2020 , 44, 1260-1269	6
836	Update on Management Periampullary/Pancreatic Head Cancer. 2020 , 1	
835	International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. 2020 , 46, 796-803	10
834	Gas Plasma-Conditioned Ringer's Lactate Enhances the Cytotoxic Activity of Cisplatin and Gemcitabine in Pancreatic Cancer In Vitro and In Ovo. 2020 , 12,	17
833	Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. 2019 , 18, 1	33

832	Statin therapy does not influence the outcome of patients undergoing surgery for pancreatic cancer. 2020 , 90, 1671-1676	1
831	Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. 2020 , 20, 125-131	13
830	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. 2020 , 22, 233-240	27
829	Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer?. 2020 , 43, 298-304	2
828	Patterns of care and treatment outcomes in patients age 80 or older with non-metastatic pancreatic cancer. 2020 , 11, 652-659	4
827	Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. 2020 , 27, 2007-2014	18
826	Imaging and Management of Pancreatic Cancer. 2020 , 41, 139-151	1
825	Significance of fistulography findings to the healing time of postoperative pancreatic fistula after pancreaticoduodenectomy. 2020 , 50, 577-584	3
824	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). 2020 , 10, e136-e146	21
823	Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer. 2020 , 20, 239-246	9
822	Carcinoma of the Pancreas. 2020 , 1342-1360.e7	0
821	A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. 2020 , 20, 254-264	20
820	Completion of adjuvant therapy in patients with resected pancreatic cancer. 2020 , 22, 241-248	9
819	Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. 2020 , 272, 366-376	24
818	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. 2020 , 17, 108-123	122
817	Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. 2020 , 50, 490-498	4
816	Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. 2020 , 20, 89-94	11
815	Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma?. 2020 , 49, e11	

814	Rare Brain Metastasis From a Pancreatobiliary Subtype of Intraductal Papillary Mucinous Neoplasm. 2020 , 49, e8-e11	1
813	A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC). 2020 , 22, 649-659	8
812	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. 2020 , 271, 996-1002	19
811	Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer. 2020 , 49, 1187-1194	3
810	Radical therapy of resectable and borderline resectable pancreatic cancer [present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?]. 2020 , 36, 142-147	
809	Prognostic relevance of the posterior resection margin for predicting disease free survival in ampullary adenocarcinoma. 2020 , 35, 211-217	
808	FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. 2020 , 12, 1758835920953294	9
807	CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. 2020 , 138, 172-181	6
806	Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. 2020 , 20, 1472-1478	1
805	Commentary: Neoadjuvant treatment of resectable pancreatic cancer: Lack of level III evidence. 2020 , 168, 1015-1016	6
804	Neoadjuvant Therapy Versus Immediate Surgery for Resectable Pancreas Cancer: Still Open for Debate. 2020 , 43, 752-754	2
803	Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence. 2021 , 106, 143-153	20
802	The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy. 2021 , 222, 159-166	2
801	The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. 2020 , 24, 34-40	4
800	Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. 2020 , 10, 16211	4
799	Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. 2020 , 168, 1048-1055	12
798	Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor location. 2020 , 20, 1123-1130	3
797	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. 2020 , 8,	10

796	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. 2020 , 25, e1681-e1690	2
795	Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. 2020 , 10, 1018	3
794	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. 2020 , 70, 375-403	72
793	Distal pancreas-coeliac axis resection with preoperative selective embolization of the coeliac axis: a single high-volume centre experience. 2020 , 405, 635-645	5
792	Immunomodulation in Pancreatic Cancer. 2020 , 12,	5
791	Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. 2020 , 12,	4
790	The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter?. 2020 , 22, 1530-1541	3
789	Survival Advantage of Upfront Surgery for Pancreatic Head Cancer Without Preoperative Biliary Drainage. 2020 , 10, 526514	3
788	Nonselective β adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival. 2020 , 3, 8-8	
787	Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. 2020 , 12, 1758835920970843	1
786	Targeted Sequencing of Pancreatic Adenocarcinomas from Patients with Metachronous Pulmonary Metastases. 2020 , 11,	
785	Development and Validation of Nomograms for Predicting Cancer-Specific Survival in Elderly Patients with Intrahepatic Cholangiocarcinoma After Liver Resection: A Competing Risk Analysis. 2020 , 12, 11015-11029	3
784	Arterial resections in pancreatic cancer - Systematic review and meta-analysis. 2020 , 22, 961-968	17
783	Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer. 2020 , 20, 1205-1212	2
782	Duktales Adenokarzinom des Pankreas [Entstehung, Diagnostik, Therapie. 2020 , 26, 977-985	
781	Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?. 2020 , 54, 49-68	3
780	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. 2020 , 38, 3185-3194	92
779	Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. 2020 , 12, 1758835920936093	15

778	Defining and Treating Borderline Resectable Pancreatic Cancer. 2020 , 21, 71	5
777	Pancreatectomy in Stage I pancreas cancer: national underutilization of surgery persists. 2020 , 22, 1703-1710	3
776	Translational Pancreatic Cancer Research. 2020 ,	1
775	Identification and Validation of Circulating Micrnas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. 2020 , 9,	6
774	Surgery for Pancreatic Cancer. 2020 , 576-586	
773	Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancreatic cancer. 2020 , 53, e12880	9
772	Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. 2020 , 20, 750	8
771	Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. 2020 , 46, 2122-2130	1
770	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. 2020 , 13,	5
769	FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06. 2020 , 49, 1372-1377	
768	Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. 2020 , 20, 1711-1717	3
767	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. 2020 , 5,	21
766	Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. 2020 , 12,	1
765	The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database. 2020 , 10, 1518	1
764	Deciphering the Role of Innate Immune NF- κ B Pathway in Pancreatic Cancer. 2020 , 12,	8
763	Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. 2020 , 11,	4
762	Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints. 2020 , 32, 384-390	2
761	Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. 2020 , 122, 1595-1603	4

760	Patterns of Failure After Adjuvant Stereotactic Body Radiation Therapy for Pancreatic Cancer With Close or Positive Margins. 2020 , 5, 1197-1205	1
759	Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). 2020 , 21, 783	4
758	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. 2020 , 12, 1758835920947969	4
757	Role of lymphadenectomy in resectable pancreatic cancer. 2020 , 405, 889-902	3
756	Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. 2020 , 5, e000578	11
755	Fifty Years of Surgery for Pancreatic Cancer. 2020 , 49, 1005-1013	2
754	Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. 2020 , 272, 481-486	55
753	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. 2020 , 272, 427-435	18
752	Cellular Heterogeneity of Pancreatic Stellate Cells, Mesenchymal Stem Cells, and Cancer-Associated Fibroblasts in Pancreatic Cancer. 2020 , 12,	11
751	The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma. 2020 , 8,	8
750	Gastrointestinal side effects of upper gastrointestinal cancer surgery. 2020 , 48-49, 101706	0
749	Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis. 2021 , 25, 1805-1814	1
748	Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. 2021 , 20, 271-278	1
747	Factors Associated with Treatment and Survival of Early Stage Pancreatic Cancer in the Era of Modern Chemotherapy: An Analysis of the National Cancer Database. 2020 , 6, 85-95	3
746	Old drug, new clinical use, no man's land for the indication: an awareness call from European experts. 2020 , 5, e000615	4
745	Duration of therapy for locally advanced pancreatic cancer: Does it matter?. 2020 , 9, 4572-4580	2
744	Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. 2020 , 123, 362-368	15
743	The Landmark Series: Intrahepatic Cholangiocarcinoma. 2020 , 27, 2859-2865	11

742	Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. 2020 , 27, 5337-5346	4
741	Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution. 2020 , 3,	1
740	Pancreatic cancer treatment: better, but a long way to go. 2020 , 50, 1117-1125	27
739	A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. 2020 , 159, 562-574	15
738	Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials. 2020 , 20, 421	5
737	Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes, and Risk Factors. 2020 , 24, 1581-1589	8
736	Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer. 2020 , 11, 231-235	6
735	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. 2020 , 29, 1586-1595	5
734	Optimal timing and treatment strategy for pancreatic cancer. 2020 , 122, 457-468	9
733	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. 2020 , 37, 61	5
732	Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. 2020 , 32, 356-363	5
731	Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern. 2020 , 47, 5175-5184	1
730	Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. 2020 , 19, 1751-1760	12
729	Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo. 2020 , 12, 4645-4665	12
728	Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. 2020 , 32, 377-383	5
727	Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer. 2020 , 9, 296-303	1
726	The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. 2020 , 20, 538	5
725	Neoadjuvant Treatment in Pancreatic Cancer. 2020 , 10, 245	58

724	Pancreatic cancer. 2020 , 5, 32		
723	The Value of Total Lymph Nodes Examined and Number of Positive Lymph Nodes in Determining the Role of Adjuvant Radiation in Pancreatic Cancer Patients. 2020 , 49, 435-441		0
722	Centralisation of Pancreatoduodenectomy in India: Where Do We Stand?. 2020 , 44, 2367-2376		3
721	Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to Pharmacodynamic Activity. 2020 , 63, 3047-3065		23
720	Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. 2020 , 49, 393-407		9
719	Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. 2020 , 43, 173-179		11
718	Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study. 2020 , 22, 1240-1249		5
717	Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. 2020 , 49, 224-229		3
716	In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma Patients. 2020 , 109, 11-17		3
715	Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. 2020 , 38, 1757-1759		12
714	Developing effective combination therapy for pancreatic cancer: An overview. 2020 , 155, 104740		21
713	Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma. 2020 , 168, 994-1002		6
712	A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. 2020 , 33, 118-125		2
711	PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer. 2020 , 52, 409-422		5
710	Pancreatic cancer. <i>Lancet, The</i> , 2020 , 395, 2008-2020	40	453
709	Tumour budding and its clinical implications in gastrointestinal cancers. 2020 , 123, 700-708		6
708	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. 2020 , 12,		12
707	Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?. 2020 , 21,		5

706	Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. 2020 , 168, 440-447	5
705	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. 2020 , 123, 709-713	13
704	Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. 2020 , 49, 837-844	3
703	Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. 2020 , 9,	6
702	Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. 2020 , 20, 1131-1138	11
701	Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. 2020 , 9, 1631-1642	5
700	Prognostic value of biomarkers in the tumor microenvironment of pancreatic ductal adenocarcinoma. 2020 , 8, 615	
699	Relevant Clinical Trials for GI Surgeons: a Review of Recent Findings. 2020 , 24, 2318-2335	
698	Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: A UK study. 2020 , 25, 100236	0
697	Targeting DNA repair in combination with radiotherapy in pancreatic cancer: A systematic review of preclinical studies. 2020 , 153, 103060	1
696	Is the Involvement of the Hepatic Artery Lymph Node a Poor Prognostic Factor in Pancreatic Adenocarcinoma?. 2020 , 98, 204-211	
695	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. 2020 , 10, 41	24
694	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. 2020 , 38, 1763-1773	290
693	Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?. 2020 , 4, 100-108	18
692	Gastrointestinal Cancers: Moving the Needle for Rectal, Gastroesophageal, Pancreaticobiliary, and Liver Cancers. 2020 , 106, 653-662	1
691	The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. 2020 , 49, 201-207	4
690	TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. 2020 , 122, 971-977	13
689	Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. 2020 , 50, 483-489	19

688	Resection Trends for Duodenal Carcinoid Tumors: A Single-Center Experience. 2020 , 49, e11-e13	2
687	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. 2020 , 12,	8
686	Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield. 2020 , 405, 43-54	5
685	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. 2020 , 49, 193-200	10
684	Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. 2020 , 10, 40	36
683	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. 2020 , 27, 2516-2524	16
682	[Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer]. 2020 , 91, 391-395	2
681	Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based study. 2020 , 20, 454-461	3
680	Small molecule inhibitors in pancreatic cancer. 2020 , 11, 164-183	8
679	Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). 2020 , 405, 23-33	8
678	Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning. 2020 , 26, 2411-2421	17
677	The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. 2020 , 50, 335-343	1
676	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. 2020 , 27, 2506-2515	6
675	Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report. 2020 , 20, 38	1
674	Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin $\beta 3$ in human pancreatic cancer. 2020 , 10, 537	4
673	Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection. 2020 , 30, 2513-2524	25
672	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. 2020 , 167, 803-811	12
671	Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. 2020 , 99, e18581	23

670	Robotic pancreaticoduodenectomy may offer improved oncologic outcomes over open surgery: a propensity-matched single-institution study. 2020 , 34, 3644-3649	18
669	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. 2020 , 10, 460	11
668	Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer. 2020 , 37, 46	10
667	Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. 2020 , 27, 1073274820915947	0
666	Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?. 2020 , 13, 2551-2562	4
665	Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression. 2020 , 46, 1516-1523	4
664	The results of pancreatic operations after the implementation of multidisciplinary team conference (MDT): A quality improvement study. 2020 , 77, 105-110	7
663	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. 2020 , 9,	37
662	Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. 2020 , 3, 1-11	9
661	Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. 2020 , 22, 1963-1975	11
660	[Neoadjuvant and adjuvant treatment of pancreatic cancer]. 2020 , 91, 636-641	
659	Combined blockade of TGF- β and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. 2020 , 69, 1477-1492	26
658	CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. 2020 , 27, 3950-3960	13
657	Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. 2020 , 15, e0231745	4
656	Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. 2020 , 26, 3732-3739	13
655	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. 2021 , 113, 27-37	9
654	Impact of Neoadjuvant Systemic Therapy on Pancreatic Fistula Rates Following Pancreatectomy: a Population-Based Propensity-Matched Analysis. 2021 , 25, 747-756	6
653	Perioperative and oncological outcomes following minimally invasive versus open pancreaticoduodenectomy for pancreatic duct adenocarcinoma. 2021 , 35, 2273-2285	9

652	Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. 2021 , 1875, 188461	19
651	Margin-Positive Pancreatic Ductal Adenocarcinoma during Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. 2021 , 28, 1552-1562	3
650	Predicting Gemcitabine Delivery by F-FAC PET in Murine Models of Pancreatic Cancer. 2021 , 62, 195-200	2
649	Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?. 2021 , 169, 403-410	6
648	Periarterial divestment in pancreatic cancer surgery. 2021 , 169, 1019-1025	22
647	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. 2021 , 28, 2246-2256	6
646	Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. 2021 , 29, 3009-3016	1
645	Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting. 2021 , 32, 133-135	
644	Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. 2021 , 28, 3779-3788	0
643	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. 2021 , 27, 1069-1081	20
642	SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. 2021 , 155, 278-284	0
641	Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis. 2021 , 28, 3186-3195	5
640	Contemporary Management of Pancreatic Cancer from an Internist Perspective. 2021 , 134, 576-586	1
639	Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment. 2021 , 259, 442-450	2
638	Chemoradiotherapy after curative surgery for locally advanced pancreatic cancer: A 20-year single center experience. 2021 , 36, 36-41	4
637	Survival impact based on hepatic artery lymph node status in pancreatic adenocarcinoma: A study of patients receiving modern chemotherapy. 2021 , 123, 399-406	1
636	Contemporary management of pancreas cancer in older people. 2021 , 47, 560-568	1
635	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. 2021 , 27, 226-236	5

634	Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies. 2021 , 123, 245-251	1
633	Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis. 2021 , 20, 74-79	2
632	Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). 2021 , 28, 1060-1068	1
631	Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study. 2021 , 28, 1572-1580	5
630	Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. 2021 , 5, 7-23	11
629	A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. 2021 , 148, 769-779	5
628	Appraisal of 5-year recurrence-free survival after surgery in pancreatic ductal adenocarcinoma. 2021 , 28, 287-296	2
627	R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 trial. 2021 , 197, 8-18	9
626	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. 2021 , 70, 606-617	49
625	Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. 2021 , 273, 587-594	31
624	Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. 2021 , 273, 154-162	51
623	Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. 2021 , 273, 341-349	121
622	Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. 2021 , 273, 579-586	59
621	Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs). 2021 , 12, 88-95	2
620	Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. 2021 , 28, 3800-3807	2
619	Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. 2021 , 50, 83-88	
618	Adjuvant Chemotherapy for Cholangiocarcinoma. 2021 , 133-142	
617	Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?). 2021 , 9, 1-12	2

616	Survival After Resection for Pancreatic Cancer. 2021 , 1135-1151	
615	Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer.. 2021 , 4, 881-884	
614	Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. 2021 , 12, 2275-2286	0
613	Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review. 2021 , 21, 43	1
612	Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection?. 2021 , 57,	0
611	Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. 2021 , 123, 970-977	1
610	Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma: A Single-Institution Experience. 2021 , 50, 64-70	
609	Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer. 2021 , 107-118	0
608	The Elderly Patient with Pancreatic Cancer: Trends and Medical Oncology. 2021 , 595-611	
607	Radiation Therapy in the Management of a Pancreatic Cancer. 2021 , 127-143	
606	Klinische Studien in der onkologischen Chirurgie. 2021 , 36, 29-34	
605	Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery?. 2021 , 12, 2450-2460	1
604	The Evolution of Adjuvant Trials in Pancreatic Cancer. 2021 , 743-761	1
603	The Quantity and Quality of Surgical Trials in Pancreatic Cancer. 2021 , 95-106	0
602	Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review. 2021 , 35, 31-39	2
601	R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. 2021 , 28, 4602-4612	8
600	Another Potential Benefit of Neoadjuvant Therapy in Pancreatic Cancer: Reduction in Postoperative Readmission Rates. 2021 , 28, 1871-1873	1
599	CHEK2 mutation in a patient with pancreatic adenocarcinoma-a rare case report. 2021 , 5, 5	0

598	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. 2021 , 15, 1186-1198	12
597	Adjuvant Chemotherapy for Pancreatic Cancer. 2021 , 75-82	
596	Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. 2021 , 406, 691-701	10
595	Adjuvant therapy for patients with resectable pancreatic ductal adenocarcinoma. 2021 , 36, 12-19	
594	Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials. 2021 , 23, 29	1
593	Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. 2021 , 38, 18	2
592	LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. 2021 , 42, 546-556	8
591	Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy. 2021 , 28, 6238-6245	1
590	The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center. 2021 , 6, 100010	4
589	Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease. 2021 , 91, 1549-1557	0
588	Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling. 2021 , 147, 1341-1354	1
587	Recent advances in precision medicine for pancreatic ductal adenocarcinoma. 2021 , 5, 457-466	4
586	Response to the Comment on "Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve". 2021 , 274, e884-e885	
585	[Diagnostics and therapy of pancreatic carcinoma]. 2021 , 146, 246-252	
584	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. 2021 , 13,	7
583	Metabolomic profiling of pancreatic adenocarcinoma reveals fundamental clinical features.	
582	Mortality and Survival Among Octogenarians with Localized Pancreatic Head Cancer: a National Cancer Database Analysis. 2021 , 25, 2582-2592	1
581	Efficacy of Adjuvant Chemotherapy after Neoadjuvant FOLFIRINOX and Following Resection of Pancreatic Cancer. 2021 , 77, 95-96	

580	Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis. 2021 , 21, 98	4
579	Targeting and Reprogramming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. 2021 , 13,	10
578	Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. 2021 , 406, 1481-1489	0
577	A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. 2021 , 7, 8-19	0
576	PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. 2021 , 6,	2
575	Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection. 2021 , 123, 1757-1763	
574	A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. 2021 ,	1
573	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. 2021 , 7, 421-427	38
572	Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do?. 2021 , 2, 80-84	
571	Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. 2021 , 27, 15-23	1
570	Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. 2021 , 44, 261-278	1
569	Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy. 2021 , 21, 110	0
568	Identification of laminin α as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. 2021 , 146, 125-134	3
567	WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. 2021 , 11, 642328	5
566	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). 2021 , 23, 988-1000	7
565	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. 2021 , 124, 1941-1948	5
564	Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. 2021 , 21, 300	22
563	Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study. 2021 , 28, 6790-6802	5

562	Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?. 2021 , 28, 6264-6272	2
561	Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma. 2021 , 19, 94	4
560	Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. 2021 , 123, 1432-1440	3
559	Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer Locations. 2021 , 11, 646082	
558	Neoadjuvant Chemotherapy in Pancreatic Cancer. 2021 , 156, 397	
557	Controversies in radiotherapy for pancreas cancer. 2021 , 123, 1460-1466	0
556	Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. 2021 , 12, 474-483	
555	History of preoperative therapy for pancreatic cancer and the MD Anderson experience. 2021 , 123, 1414-1422	2
554	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. 2021 , 9,	8
553	Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. 2021 , 123, 1423-1431	1
552	Invited Commentary. 2021 , 232, 514-516	
551	Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer. 1-8	0
550	Neoadjuvant Chemotherapy in Pancreatic Cancer-Reply. 2021 , 156, 398	1
549	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. 2021 , 13,	3
548	Seminars in surgical oncology-Pancreas cancer adjuvant therapy trials. 2021 , 123, 1467-1474	1
547	3d tissue models as tools for radiotherapy screening for pancreatic cancer. 2021 , 94, 20201397	3
546	Pancreatic Cancer Exposome Profile to Aid Early Detection and Inform Prevention Strategies. 2021 , 10,	2
545	Adjuvant chemotherapy versus observation following neoadjuvant therapy and surgery for resectable stages III pancreatic cancer. 1-10	

544	Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. 2021 , 12, 446-454	
543	Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. 2021 , 21, 573-580	2
542	Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. 2021 , 124, 308-316	2
541	The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. 2021 , 270, 119118	3
540	Surgical Treatment of Pancreatic Ductal Adenocarcinoma. 2021 , 13,	8
539	Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. 2021 , 16, e0249885	0
538	Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. 2021 , 11, 7499	1
537	Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. 2021 , 66, 103332	5
536	The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis. 2021 , 100, e25398	
535	Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. 2021 , 147, 17-28	6
534	Neoadjuvant Treatment of Pancreatic Cancer. 2021 , 488-500	
533	Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. 2021 , 50, 529-536	
532	Adjuvant Therapy in Pancreatic Cancer. 2021 , 501-505	
531	Evaluation of the significance of adjuvant chemotherapy in patients with stage IA pancreatic ductal adenocarcinoma. 2021 , 21, 581-588	3
530	Achieving 'Marginal Gains' to Optimise Outcomes in Resectable Pancreatic Cancer. 2021 , 13,	1
529	Pitavastatin and metformin synergistically activate apoptosis and autophagy in pancreatic cancer cells. 2021 , 36, 1491-1503	5
528	Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma. 2021 , 11, 683289	0
527	Treatment landscape of metastatic pancreatic cancer. 2021 , 96, 102180	18

526	Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. 2021 , 11, 651119	1
525	Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. 2021 , 7, 735-738	30
524	A Novel Validated Recurrence Stratification System Based on F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. 2021 , 11, 650266	1
523	Systemische Therapie des duktaalen Pankreaskarzinoms. 2021 , 24, 37-47	
522	The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?. 2021 , 28, 124-128	2
521	The importance of multimodal therapy in the management of nonmetastatic adenosquamous carcinoma of the pancreas: Analysis of treatment sequence and strategy. 2021 , 169, 1102-1109	1
520	LINC00460 promotes pancreatic cancer progression by sponging miR-491-5p. 2021 , 23, e3333	3
519	Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. 2021 , 21, 1326-1341	1
518	Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. 2021 , 28, 7759-7769	1
517	Which patients benefit from preoperative biliary drainage in resectable pancreatic cancer?. 2021 , 15, 855-863	0
516	Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol. 2021 , 11, e042067	2
515	Resected pancreatic adenocarcinoma: An Asian institution's experience. 2021 , 4, e1393	1
514	Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. 2021 , 25, 179-191	1
513	Curing pancreatic cancer. 2021 , 76, 232-246	2
512	The Landmark Series: Preoperative Therapy for Pancreatic Cancer. 2021 , 28, 4104-4129	2
511	MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. 2021 , 21, 340-355	2
510	Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights. 2021 , 22,	0
509	Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. 2021 , 150, 250-259	1

508	Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021). 2021 , 4, 49-66	2
507	Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?. 2021 , 22,	4
506	Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. 2021 , 27, 3037-3049	4
505	Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study. 2021 , 50, 375-382	
504	Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines. 2021 , 13,	10
503	Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. 2021 , 26, 1911-1921	1
502	Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. 2021 , 21, 787-795	2
501	What do surgeons need to know about the mesopancreas. 2021 , 1	1
500	The effect of atrial fibrillation on perioperative outcomes in patients with pancreatic cancer undergoing open pancreaticoduodenectomy: analysis of the National Inpatient Sample. 2021 , 10, 1951-1961	
499	TNF- β induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. 2021 , 12, 649	7
498	Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma. 2021 , 88, 619-631	3
497	Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. 2021 , 21, 796-804	1
496	Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. 2021 , 10,	0
495	Advances in the management of pancreatic ductal adenocarcinoma. 2021 , 193, E844-E851	2
494	Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validation. 2021 , 28, 671-679	2
493	Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients with Pancreatic Ductal Adenocarcinoma. 2021 ,	2
492	Trends in the treatment of pancreatic cancer in Japan. 2021 , 15, 135-137	0
491	Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. 2021 , 27, 3158-3181	4

490	Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer. 2021 , 13,	2
489	The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. 2021 , 4, e1390	1
488	The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes. 2021 ,	1
487	Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. 2021 ,	0
486	Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis. 2021 , 124, 801-809	0
485	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. 2021 , 11, 688377	8
484	The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. 2021 , Publish Ahead of Print,	1
483	Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development. 2021 , 13,	4
482	[Pylorus-Preserving Pancreaticoduodenectomy (PPPD) with Segmental Portal Vein Resection]. 2021 ,	
481	Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. 2021 , 156, 663-672	6
480	Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. 2021 , 11, 670396	4
479	[Surgery for periampullary pancreatic cancer]. 2021 , 92, 776-787	
478	Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. 2021 , e1507	
477	Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. 2021 , 28, 8249-8260	5
476	Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. 2021 , 274, 713-720	6
475	Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. 2021 , 13,	3
474	Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer. 2021 , 23, 300-306	
473	Geriatrische gastrointestinale Onkologie: Leber, Galle, Pankreas. 2021 , 16, 378-386	

472	Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma. 2021 , 21, 1371-1377	4
471	Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. 2021 , 11, 695627	2
470	Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids.	0
469	GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma.	
468	Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database. 2021 , 1	2
467	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. 2021 , 21, 936	1
466	"Mesopancreas-first" radical resection of pancreatic head cancer following the Cattell-Braasch-Valdoni maneuver: Appreciating the legacy of pioneers in visceral surgery. 2021 , 25, 376-385	0
465	UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. 2021 , 9, 860	5
464	CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B. 2021 , 9, 667551	1
463	Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis. 2021 , 15, 1276	1
462	Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?. 2021 , 13,	0
461	Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors?. 2021 , 170, 1807-1814	1
460	Pre-Operative MDCT Staging Predicts Mesopancreatic Fat Infiltration-A Novel Marker for Neoadjuvant Treatment?. 2021 , 13,	0
459	. 2021 , 193, E1362-E1370	
458	Can Pancreatic Organoids Help in the Treatment of Pancreatic Cancer?. 2021 , 55, 215-229	
457	Postoperative and long-term survival in relation to life-expectancy after pancreatic surgery in elderly patients (cohort study). 2021 , 69, 102724	
456	Cholesterol biosynthesis inhibitor RO 48-8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway. 2021 , 24,	0
455	Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature. 1	0

454	Pancreatic cancer in 2021: What you need to know to win. 2021 , 27, 5851-5889	7
453	NF- κ B and Pancreatic Cancer; Chapter and Verse. 2021 , 13,	6
452	Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection. 2021 , 11, 660215	0
451	Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. 2021 ,	0
450	Prognostic Value of Preoperative NLR and Vascular Reconstructive Technology in Patients With Pancreatic Cancer of Portal System Invasion: A Real World Study. 2021 , 11, 682928	0
449	Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. 2021 ,	2
448	Paraaortic dissection in "total mesopancreas excision" and "mesopancreas-first resection" pancreaticoduodenectomies for pancreatic cancer: Useless, optional, or necessary?A systematic review. 2021 , 38, 101639	0
447	Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma. 2021 , 10, 7233-7241	3
446	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. 2021 , 99, 102208	1
445	Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019. 2021 , 28, 3629-3648	1
444	Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. 2021 , 13,	2
443	Locally advanced pancreatic cancer: a reliable contraindication to resection in the modern era?. 2021 ,	
442	Treatment Approach to Adenocarcinoma of the Ampulla of Vater. 2021 , 22, 103	1
441	Pancreatic Cancer: A Review. 2021 , 326, 851-862	69
440	Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta-Analysis. 2021 , 1	0
439	Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. 2021 , 30, 657-671	
438	Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. 2021 , 30, 719-730	0
437	Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and AFACT trials. 2021 , 27, 1367-1375	1

436	Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer. 2021 , 10, 714-716	1
435	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). 2021 , 157, 21-30	3
434	Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. 2021 , 13, 17588359211045861	2
433	Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?. 2021 , 28, 1884-1886	1
432	Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study. 2021 , 28, 1896-1905	2
431	Neoadjuvant treatment of localized pancreatic adenocarcinoma. 2021 , 12, 2461-2474	
430	Pankreas. 2021 , 621-674	
429	Cancer du pancréas. 2021 , 153-190.e3	
428	Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison. 2021 , 44, 476-484	2
427	The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. 2021 , 51, 604-611	1
426	Pancreatoduodenectomy with Portal Vein Resection. 2021 , 847-862	
425	The role of PARP inhibitors in mutated pancreatic cancer. 2021 , 14, 17562848211014818	9
424	Imaging Diagnostics in Pancreatic Cancer from the Perspective of an Oncologist. 2021 , 109-126	
423	[Cancers of the pancreas at the National Hospital and University Center of Cotonou: epidemiological, diagnostic, therapeutic and prognostic features]. 2021 , 39, 18	
422	A novel risk-scoring system conducting to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. 2021 , 12, 4433-4442	0
421	Surveillance After Surgery for Pancreatic Cancer. 2021 , 1121-1133	
420	Neoadjuvant Therapy in Upfront Resectable Pancreatic Cancer. 2021 , 697-712	
419	Preoperative Therapy in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. 2021 , 729-741	

418 Pancreas. **2021**, 211-225

417 Căncer de pâncreas. **2021**, 13, 1345-1352

416 Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP. **2021**, 28, 3810-3822 2

415 Clinical impact of preoperative tumour contact with superior mesenteric-portal vein in patients with resectable pancreatic head cancer. **2021**, 406, 1443-1452 0

414 Surgery for locally advanced pancreatic ductal adenocarcinoma-is it only about the vessels?. **2021**, 12, 2503-2511 0

413 A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. **2021**, 26, 941-950 3

412 Evidence-Based Screening for Recurrence. **2021**, 287-308

411 The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. **2021**, 22, 23-40 12

410 Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. **2021**, 70, 2165-2177 6

409 Metabolic Biomarkers of Pancreatic Cancer. **2020**, 83-96 1

408 [Surgery of pancreatic cancer: techniques to avoid local recurrence]. **2020**, 91, 615-627 2

407 Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. **2020**, 55, 369-382 13

406 Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome. **2020**, 2 2

405 Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. **2020**, 22, 1542-1548 3

404 Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295). **2020**, 43, 857-860 2

403 Impact of Complications After Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission: Analysis of a Nationwide Audit. **2020**, 275, 6

402 Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. **2020**, 275, 9

401 Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds?. **2020**, 17

400	A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. 2021 , 274, e82-e84	6
399	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. 2020 ,	1
398	Meta-analysis of 1,200 transcriptomic profiles identifies a prognostic model for pancreatic ductal adenocarcinoma.	2
397	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. 2020 , 26, 2318-2326	28
396	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. 2021 , 27, 1278-1286	11
395	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. 2020 , 5,	17
394	Recent advances in the treatment of pancreatic cancer. 2020 , 9,	23
393	Validation of full-field optical coherence tomography in distinguishing malignant and benign tissue in resected pancreatic cancer specimens. 2017 , 12, e0175862	12
392	The Clinical Benefit of Adjuvant Therapy in Long-Term Survival of Early-Stage Ampullary Carcinoma: A Single Institutional Experience. 2020 , 12, 560-567	2
391	Pattern of care and survival of pancreatic ductal adenocarcinoma in a multi-disciplinary high-volume centre. 2018 , 9,	1
390	Evolution of surgery for pancreatic head and periampullary cancer. 2019 , 24, 45-53	2
389	The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. 2019 , 3, 9-14	9
388	Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. 2020 , 12, 19585-19596	3
387	Germline mutations in pancreatic cancer and potential new therapeutic options. 2017 , 8, 73240-73257	33
386	Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature. 2017 , 8, 73345-73361	22
385	The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. 2018 , 9, 28069-28082	4
384	Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma. 2019 , 10, 7276-7287	5
383	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. 2020 , 11, 3489-3501	13

382	Adjuvant therapy in invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a systematic review. 2019 , 7, 689	7
381	Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. 2017 , 6, 31	12
380	Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Bio- markers in Pancreatic Cancer. 2019 , 20, 569-580	9
379	Receipt of Curative Resection or Palliative Care for Hepatopancreaticobiliary Tumours (RICOCHET): Protocol for a Nationwide Collaborative Observational Study. 2019 , 8, e13566	4
378	Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. 2020 , 12,	10
377	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. 2020 , 12,	8
376	Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. 2019 , 25, 2839-2845	6
375	Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma. 2018 , 36, 210-217	1
374	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. 2021 , 53, 1096-1103	2
373	Sarcopenia in pancreatic cancer - effects on surgical outcomes and chemotherapy. 2019 , 11, 527-537	26
372	Evolving treatment landscape for early and advanced pancreatic cancer. 2017 , 9, 281-292	19
371	Long term oncological outcome of laparoscopic techniques in pancreatic cancer. 2018 , 10, 383-391	6
370	Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. 2020 , 11, 747-760	4
369	Pancreatic Adenocarcinoma, Version 1.2019. 2019 , 17, 202-210	179
368	Cancer of Exocrine Pancreas. 2021 , 645-674	
367	How to select the most appropriate adjuvant treatment after neoadjuvant treatment and resection for locally advanced pancreatic cancer?. 2021 , 12, 2521-2535	
366	Present status and perspective of perioperative chemotherapy for patients with resectable pancreatic cancer in Japan.. 2022 , 4, 14-20	
365	Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom?. 2021 ,	0

- 364 'Fast-track' pathway for resectable pancreatic cancer: barriers and facilitators to implementation across a regional network. **2021**, 8, e717-e721
- 363 Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma.. **2022**, 275, 415-421 1
- 362 Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. **2021**, 27, 6572-6589 4
- 361 Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer. **2021**, 22, 90-98 2
- 360 Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma. **2021**, 1 2
- 359 Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. **2021**, 1 1
- 358 Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection. **2021**, 2021, 3809095 0
- 357 Parachute technique for portal vein reconstruction during pancreaticoduodenectomy with portal vein resection in patients with pancreatic head cancer. **2021**, 1 1
- 356 Neues zur Therapie des Pankreaskarzinoms: Hoffnung am Horizont?. **2021**, 2, 138
- 355 Clinical Characteristics of Resected Acinar Cell Carcinoma of the Pancreas: A Korean Multi-Institutional Study. **2021**, 13, 1 1
- 354 Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. **2021**, 27, 6527-6550 3
- 353 Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. **2021**, 39, 3773-3777 3
- 352 The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. **2021**, 13, 1 1
- 351 Adjuvant Chemotherapy in Pancreatic Cancer. **2016**, 1-34 1
- 350 Venous Resection in Pancreatic Cancer Surgery. **2017**, 1-26 1
- 349 Borderline Resectable Pancreatic Cancer. **2017**, 1-21 1
- 348 Circulating Tumour Cells. **2017**, 1-36 1
- 347 Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma. **2017**, 1-34 1

- 346 Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?. **2017**, 6, S62-S65 1
- 345 Anaplastic Pancreatic Carcinoma Arising Within a Mucinous Cystic Neoplasm of the Pancreas: A Case Report and a Brief Review of the Literature. **2017**, 3, 40-45
- 344 Current and Emerging Therapies in Pancreatic Cancer: Do They Provide Value?. **2018**, 361-367
- 343 Pankreas. **2018**, 483-529
- 342 Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study. **2018**, 23, 108-115 0
- 341 The Future of Multidisciplinary Care in Pancreatic Cancer. **2019**, 1-7
- 340 Treatment Sequencing for Resectable Disease. **2019**, 47-53
- 339 Neoadjuvant Chemoradiation for Localized Pancreatic Cancer. **2019**, 85-96
- 338 Resectable and Borderline Resectable Pancreatic Cancer. **2019**, 235-254
- 337 Pancreatic Cancer. **2019**, 261-276
- 336 Importance of Carbohydrate Antigen 19-9 Monitoring in the Management of Pancreatic Cancer. **2019**, 39-45
- 335 Role of 18F-Fluorodeoxyglucose Positron-Emission Tomography (FDG-PET) in the Management of Pancreatic Cancer. **2019**, 175-185
- 334 A New Era in the Adjuvant Treatment of Pancreatic Adenocarcinoma. **2019**, 10, 915-919
- 333 Delivery of Neoadjuvant Versus Adjuvant Therapy in Localized Pancreatic Cancer. **2019**, 67-84
- 332 Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. **2019**, 11, 102-116 0
- 331 Preoperative CA19-9 levels predict disease-free survival and overall survival in pancreatic adenocarcinoma patients after resection.. **2019**, 8, 811-820 0
- 330 The role of laparoscopic pancreaticoduodenectomy-how take care of patient security?. **2019**, 7, S94
- 329 The role of systemic therapy in localized pancreatic cancer (review). **2019**, 24, 65-72

- 328 Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis.. **2019**, 3, 1-22 1
- 327 DUPLICATE: Imaging and Management of Pancreatic Cancer. **2019**,
- 326 Adenocarcinoma of the Pancreas. **2020**, 415-435
- 325 Factors affecting survival in operated pancreatic cancer: Does tumor localization have a significant effect on treatment outcomes?. **2020**, 7, 487-493
- 324 Is the involvement of the hepatic artery lymph node a poor prognostic factor in pancreatic adenocarcinoma?. **2020**, 98, 204-211
- 323 Comment on "Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma". **2021**, 274, e718
- 322 Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: evidence from 20 randomized controlled trials.
- 321 PancREatic Cancer and Individualised Supervised Exercise (PRECISE): a feasibility trial protocol for patients with resectable pancreatic ductal adenocarcinoma. 2, 22
- 320 Detection of Chemotherapy-Resistant Pancreatic Cancer Using a Glycan Biomarker.
- 319 PancREatic Cancer and Individualised Supervised Exercise (PRECISE): a feasibility trial protocol for patients with resectable pancreatic ductal adenocarcinoma. 2, 22
- 318 Multimodality therapy in metastatic pancreas cancer with a mutation and durable long-term outcome: biology, intervention, or both?. **2021**, 1-5
- 317 Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer. **2021**, 2021, 78
- 316 Diagnostik und Therapie des Pankreaskarzinoms. **2021**, 42, 655-661
- 315 Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. **2020**, 3, 2
- 314 Duktales Adenokarzinom des Pankreas [Entstehung, Diagnostik, Therapie. **2021**, 16, 41-50 0
- 313 Nonsurgical Management of Pancreatic Adenocarcinoma. **2021**, 1-22
- 312 Preoperative prognostic factors in patients with ductal adenocarcinoma of the head of the pancreas. **2020**, 47, e20202363
- 311 ERKRANKUNGEN DER VERDAUUNGSORGANE. **2020**, pA-1-pA7.8-14

- 310 Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for Protein Biomarkers. **2020**, 73-82
- 309 [Medicinal treatment of pancreatic cancer : Still a domain of chemotherapy?]. **2020**, 61, 226-232
- 308 Circulating Tumor DNA as a Novel Biomarker for Pancreatic Cancer. **2020**, 107-116
- 307 Adjuvant therapy. **2020**, 35, 58-62
- 306 Current perspective on the treatment of advanced pancreatic adenocarcinoma. **2020**, 14, 37-39
- 305 Circulating tumor DNA as specific biomarkers for early diagnosis and prognosis of pancreatic cancer. **2019**, 11, 11-17
- 304 The role of radiation for pancreatic adenocarcinoma. **2020**, 3, 72-80 2
- 303 Pancreatic cancer treatment. **2020**, 35, 193-200
- 302 State-of-the-art surgery for pancreatic cancer. **2021**, 1 1
- 301 Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. **2021**, 1-13
- 300 A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. **2021**,
- 299 Clinical Impact of Molecular Subtyping of Pancreatic Cancer. **2021**, 9, 743908 4
- 298 Surgery for pancreatic cancer: current controversies and challenges. **2021**, 17, 5135-5162 1
- 297 Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. **2020**, 25, 72-82 1
- 296 Advances in the Management of Pancreatic Adenocarcinoma. **2020**, 18, 958-961 0
- 295 Adjuvant nab-paclitaxel plus gemcitabine gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. **2020**, 8, 2778-2786
- 294 Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. **2020**, 2020, 5304516
- 293 Selection of Optimal Adjuvant Chemotherapeutic Agents for Pancreatic Cancer Treatment. **2020**, 95, 315-319

292	Neoadjuvant chemotherapy followed by total pancreatectomy with splenectomy and combined vascular resections after preoperative percutaneous transhepatic portal vein stent placement in locally advanced pancreatic cancer with portal vein total obliteration. 2020 , 24, 551-556	
291	A proposal for the ideal algorithm for the diagnosis, staging, and treatment of pancreas masses suspicious for pancreatic adenocarcinoma: Results of a working group of the Canadian Society for Endoscopic Ultrasound. 2020 , 9, 154-161	4
290	New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. 2020 , 21, 108-111	0
289	Is There any Survival Benefit of Maintenance Chemotherapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer Patients with Post-Surgery Elevated CA 19-9?. 2020 , 21, 74-80	
288	Neoadjuvant therapy vs. upfront surgery for resectable pancreatic cancer: An update on a systematic review and meta-analysis. 2021 , 15,	0
287	The potential roles of p53 signaling reactivation in pancreatic cancer therapy. 2021 , 1877, 188662	1
286	Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. 2021 ,	1
285	A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. 2021 ,	1
284	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. 2021 , 13,	1
283	Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. 2021 , 11,	3
282	Resection of Recurrent Pancreatic Cancer: Who Can Benefit?. 2022 , 38, 42-48	0
281	Paradigm shift for defining the resectability of pancreatic cancer. 2021 , 25, 451-455	0
280	Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma. 2021 , 27, 7480-7496	2
279	Diagnostik und Therapie des Pankreaskarzinoms. 2021 , 12, 265-271	
278	ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Recurrence. 2021 , 1	
277	Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pancreatic cancer therapy. 2021 , 280, 121264	0
276	On the Evaluation of a Novel Hypoxic 3D Pancreatic Cancer Model as a Tool for Radiotherapy Treatment Screening. 2021 , 13,	1
275	Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. 2021 ,	1

- 274 Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.. **2021**, 100, e27870 0
- 273 Onkologika. **2021**, 579-638
- 272 The impact of nutritional status on pancreatic cancer therapy.. **2022**, 1
- 271 The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.. **2021**, 40, 101694
- 270 A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis.. **2022**, 1
- 269 Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution.. **2022**, 20, 11 2
- 268 Evolving pancreatic cancer treatment: From diagnosis to healthcare management.. **2021**, 169, 103571 2
- 267 Target c-Myc to treat pancreatic cancer.. **2022**, 1-17 6
- 266 Landmark Series: Importance of Pancreatic Resection Margins.. **2022**, 29, 1542 2
- 265 Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study.. **2022**, 2
- 264 Radiation therapy in borderline resectable pancreatic cancer: A review.. **2022**, 0
- 263 Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling.. **2022**, 38, 20-29 1
- 262 Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort.. **2022**, 6, 2
- 261 Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.. **2022**, JCO2102233 12
- 260 Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis.. **2022**, 6, 3
- 259 Das Pankreaskarzinom. **2022**, 28, 30
- 258 Early discontinuation of adjuvant chemotherapy in patients with early-stage pancreatic cancer correlates with inferior survival: A multicenter population-based cohort study.. **2022**, 17, e0263250
- 257 Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis.. **2022**, 11, 0

256	ASO Author Reflections: An Underappreciated Metric: Systemic Chemotherapy Dose Density in Pancreatic Cancer.. 2022 , 1	
255	Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma.. 2022 ,	0
254	Data of 'Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage'.. 2022 , 41, 107944	
253	Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma.. 2022 ,	2
252	Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head.. 2022 , 14,	0
251	Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer.. 2022 ,	
250	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.. 2022 , e1565	2
249	Comment on "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis" .. 2022 ,	
248	Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough?. 2022 , 1	1
247	Comparisons of Outcomes Between Adolescent and Young Adult with Older Patients After Radical Resection of Pancreatic Ductal Adenocarcinoma by Propensity Score Matching: A Single-Center Study.. 2021 , 13, 9063-9072	
246	The Problem of Malignancy of the Pancreas: Relevance, Diagnostic Difficulties, Reality and Prospects (on a Clinical Example). 2021 , 838-845	
245	Predictive Model of Early Death of Resectable Pancreatic Ductal Adenocarcinoma After Curative Resection: A SEER-Based Study.. 2022 , 29, 10732748221084853	
244	Pankreas. 2022 , 421-448	
243	Hepatopancreaticobiliary Cancer in Older Adults with Frailty. 2022 , 421-445	
242	A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC).. 2022 , 14,	1
241	Rational Design of an Orally Active Anticancer Fluoropyrimidine, Pencitabine, a Hybrid of Capecitabine and Gemcitabine.. 2022 , 13, 409-416	
240	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.. 2022 ,	0
239	The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain.. 2022 ,	1

238	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. 2021 , 11, 744161	0
237	Results of a Phase II Study on the use of Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine with nab-paclitaxel) for Borderline-Resectable Pancreatic Cancer (NUPAT-01).. 2022 ,	3
236	Influence of sarcopenia as defined by EWGSOP2 on complications after pancreaticoduodenectomy and on the prognosis of pancreatic head cancer: A prospective cohort study.. 2022 , 99-100, 111660	
235	Impact of the aberrant right hepatic artery on local recurrence of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.. 2022 ,	0
234	What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma?. 2021 ,	1
233	Development and Validation of Nomograms to Predict Overall Survival and Cancer-Specific Survival in Patients With Pancreatic Adenosquamous Carcinoma.. 2022 , 12, 831649	0
232	Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice.. 2022 , 14,	0
231	Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer.. 2021 ,	0
230	Clinical Analysis of Bloodstream Infection of in Patients with Pancreatic Cancer from 2011 to 2019.. 2022 , 2022, 1338188	0
229	Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma?. 2022 , 1	1
228	The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer.. 2022 ,	2
227	Pancreatic cancer. 2022 , 40, 237-248	
226	[Future concepts for neoadjuvant and adjuvant treatment of (resectable) pancreatic cancer].. 2022 , 1	0
225	[Evidence for Neoadjuvant Therapy in Resectable Pancreatic Cancer].. 2022 , 147, 168-172	0
224	Early-onset pancreatic cancer: Clinical characteristics and survival outcomes.. 2022 ,	0
223	[Ampullary Carcinoma-prognostic and Therapeutical Contrast to Pancreatic Ductal Adenocarcinoma].. 2022 , 147, 160-167	
222	The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion.. 2022 , 1	1
221	Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?. 2022 , 41, 101735	0

- 220 Polyhedral oligomeric silsesquioxane (POSS)-based hybrid nanocomposite for synergistic chemo-photothermal therapy against pancreatic cancer. **2022**, 442, 136124 ○
- 219 ONIVYDE - New treatment option for better survival in patients with metastatic pancreatic adenocarcinoma. **2021**, 15, 182-186
- 218 Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.. **2021**, 1
- 217 Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer.. **2021**, 14, ○
- 216 Advances in the Detection of Pancreatic Cancer Through Liquid Biopsy.. **2021**, 11, 801173 ○
- 215 Surgical resection is associated with improved long-term survival of patients with resectable pancreatic head cancer compared to multiagent chemotherapy.. **2021**,
- 214 Perioperative and long-term outcome of en-bloc arterial resection in pancreatic surgery.. **2021**,
- 213 Entwicklung der Chirurgie im Wandel der multimodalen Therapien beim Pankreaskarzinom. **2021**, 15, 493-510
- 212 Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society. **2021**, 1
- 211 Robotic versus Open Pancreatoduodenectomy for Pancreatic and Periampullary Tumors (PORTAL): a study protocol for a multicenter phase III non-inferiority randomized controlled trial.. **2021**, 22, 954 ○
- 210 Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis.. **2021**, 14, ○
- 209 Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro. **2021**, 4, 170-177
- 208 Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice.. **2021**, 11, 791946
- 207 Neoadjuvant Chemotherapy Based on Gemcitabine and FOLFIRINOX: Survival and Death of Cancer Cells in Patients with Adenocarcinoma of the Pancreatic Ducts. **2020**, 77-87
- 206 Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.. **2022**,
- 205 Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.. **2022**, ○
- 204 Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings.. **2022**, 151, 110313
- 203 Time to Neoadjuvant Chemotherapy Initiation is not Associated With Survival in Pancreatic Cancer.. **2022**, 276, 369-378

202 Data_Sheet_1.docx. **2020,**

201 Data_Sheet_2.docx. **2020,**

200 Image_1.pdf. **2019,**

199 Image_1.TIF. **2020,**

198 Table_6.docx. **2018,**

197 Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.. **2022,** 0

196 A proposal for the ideal algorithm for the diagnosis, staging, and treatment of pancreas masses suspicious for pancreatic adenocarcinoma: Results of a working group of the Canadian Society for Endoscopic Ultrasound. **2020,** 9, 154 5

195 Real-world outcomes of adjuvant gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma.. **2022,** 14, 17588359221097190

194 Pancreatic cancer - the past, the present, and the future.. **2022,** 1-9 2

193 Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?. **2022,** 11, 1

192 Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.. **2022,** 12, 860767 0

191 Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives.. **2022,** 9, 839339 0

190 Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress?. **2022,** 0

189 Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. **2022,** 9, 1

188 Clinicopathological features of gastric cancer after pancreaticoduodenectomy: reporting of three institutional cases and review of the global literature.. **2022,**

187 Efficacy and safety of S-1 based adjuvant chemoradiotherapy for resected pancreatic ductal adenocarcinoma with high-risk pathological feature: a prospective, single-arm, interventional study. **4,** Publish Ahead of Print,

186 Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. **2022,** 2, 35-45

185 Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial.. *Lancet, The,* **2022,** 40 1

- 184 Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.. **2022**, 11, 2066767 3
- 183 Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.. **2022**, 169, 20-31 1
- 182 The Effect of Increase in Clinical Experience on Morbidity and Mortality After Pancreaticoduodenectomy Surgery. **2021**, 94, 1-5
- 181 Pancreatic Cancer. **2022**, 341-353
- 180 Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.. **2022**, 7, 100485 1
- 179 Molecular Mechanism of Curcumin and Its Analogs as Multifunctional Compounds against Pancreatic Cancer.. **2022**, 1-13 0
- 178 Estimation of the organ of origin of peri-ampullary malignancy by preoperative CT scan.. **2022**, 2841851221096284
- 177 Neoadjuvant treatment in localized and resectable cancer of the pancreas: a new therapeutic paradigm. **2022**,
- 176 Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma.
- 175 Systemic Therapies for Pancreatic Cancer. **2022**, 193-200
- 174 Surgical Approach to Pancreas, Liver, Biliary Physiologic Impairment. **2022**, 31-49
- 173 Chemotherapy in Pancreatic Ductal Adenocarcinoma. **2022**, 171-176
- 172 From prehab to rehab: nutritional support for people undergoing pancreatic cancer surgery. 1
- 171 Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options. **2022**, 20, 600-602
- 170 Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. **2022**, 114504 1
- 169 Pancreatic cancer. **2023**, 366-369
- 168 Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. 0
- 167 Gastrointestinal Surgery. **2022**, 97-135

- 166 The Role of Surgery in Managing Primary and Metastatic Hepatopancreaticobiliary Cancers. **2022**, 431-443
- 165 Trends in the surgical treatment for pancreatic cancer in the last 30 years. **2022**,
- 164 Case 19-2022: A 29-Year-Old Woman with Jaundice and Chronic Diarrhea. **2022**, 386, 2413-2423 ○
- 163 Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity. **2022**, 9, ○
- 162 Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. **2022**, 5, e2218355 ○
- 161 Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al.
- 160 Patterns of recurrence after primary local therapy for pancreatic ductal adenocarcinoma: a critical review of rationale and target delineation for (neo)adjuvant radiotherapy. **2022**, 1
- 159 Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study. **2022**, 14, 1175-1186 ○
- 158 Diagnostik, Staging und Therapie des Pankreaskarzinoms. **2022**, 9, 24-33
- 157 Survival Analysis and Prediction Model of ASCP Based on SEER Database. 12, ○
- 156 Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting. **2022**, 14, 2879
- 155 Tumor Location in the Pancreatic Tail Is Associated with Decreased Likelihood of Receiving Chemotherapy for Pancreatic Adenocarcinoma.
- 154 Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. Publish Ahead of Print, 1
- 153 Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
- 152 The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. ○
- 151 Multimodal Therapies Against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches Towards Ultimate Nanomedicine Treatments. 2200079 2
- 150 Periplocin Induces Apoptosis of Pancreatic Cancer Cells through Autophagy via the AMPK/mTOR Pathway. **2022**, 2022, 1-13
- 149 Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Using Optical Surface Management System Δ AlignRT as an Optical Body Surface Motion Management in Deep Breath Hold Patients: Results from a Single-Arm Retrospective Study. Volume 14, 2161-2172

148	Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma. 2022 , 14, 3494	1
147	Independent validation and assay standardization of improved metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. 2022 ,	2
146	Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma. Publish Ahead of Print,	
145	Ginsenoside Rh4 Suppresses Metastasis of Esophageal Cancer and Expression of c-Myc via Targeting the Wnt/ β Catenin Signaling Pathway. 2022 , 14, 3042	0
144	Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. 2022 , 28, 3637-3643	1
143	Label-free differentiation of human pancreatic cancer, pancreatitis, and normal pancreatic tissue by molecular spectroscopy. 2022 , 27,	0
142	Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. 2022 , 104, 106786	
141	Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma.	0
140	Delayed Gastric Emptying Does Not Influence Cancer-Specific Survival after Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. 2022 , 11, 4200	
139	Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials. 2022 , 38, 521-531	1
138	Predictors, Patterns, and Timing of Recurrence Provide Insight into the Disease Biology of Invasive Carcinomas Arising in Association with Intraductal Papillary Mucinous Neoplasms.	
137	Neoadjuvant therapy for resectable pancreatic cancer: a narrative review. Publish Ahead of Print,	0
136	Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial. 2022 , 22,	
135	Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being.	1
134	Uniform expansion vs. non-uniform expansion of gross tumor volume based on recurrence patterns to form planning target volume of stereotactic body radiation therapy for locally advanced pancreatic cancer: protocol of a randomized phase II study.	
133	Combined Systemic Drug Treatment with Proton Therapy: Investigations on Patient-Derived Organoids. 2022 , 14, 3781	1
132	Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of pancreatic cancer. 2022 ,	0
131	Surgical Approach does not Affect Return to Intended Oncologic Therapy Following Pancreatoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched Study.	0

130	Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon. 2022 , 39,	
129	Oncological outcomes of robotic pancreatectomy in patients with pancreatic cancer who receive adjuvant chemotherapy: A propensity score-matched retrospective cohort study. 2022 , 104, 106801	
128	Advances in the Surgical Treatment of Pancreatic Cancer. 2022 ,	
127	Drug-induced tumor-specific cytotoxicity in a whole tissue 'ex vivo' model of human pancreatic ductal adenocarcinoma. 12,	1
126	Nonsurgical Management of Pancreatic Adenocarcinoma. 2022 , 535-556	0
125	Serious complications of pancreatoduodenectomy correlate with lower rates of adjuvant chemotherapy: Would high-risk patients benefit from neoadjuvant therapy?. 2022 ,	0
124	Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma. 2022 ,	0
123	Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. 2022 , 58, 1298	0
122	The crucial role of LncRNA MIR210HG involved in the regulation of human cancer and other disease.	0
121	Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. 2022 , 11, 3068	0
120	Prognostic Significance of Initial Absolute Lymphocyte Count in Adjuvant Radiotherapy for Pancreatic Adenocarcinoma. 2022 , 10, 2190	0
119	Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. 12,	0
118	Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. 12,	0
117	Radiotherapy for Pancreatic Adenocarcinoma. 2022 ,	1
116	Pancreatic Adenocarcinoma Management.	4
115	Stereotactic body radiation therapy for pancreatic cancer: a potential ally in the era of immunotherapy?. 2022 , 40, 169-171	0
114	A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy. 2022 , 3, e198	0
113	Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. 2022 , 14, 4360	1

112	GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. <i>gutjnl-2021-325803</i>	1
111	Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. 2022 , 15, 1199	1
110	Survival outcomes of surgical and non-surgical treatment in elderly patients with stage I pancreatic cancer: A population-based analysis. 9,	0
109	Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.	1
108	Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. 1-11	1
107	Management of Resectable and Borderline Resectable Disease: Medical Oncology. 2022 , 139-151	0
106	Patient Reported Outcomes and Quality of Life. 2022 , 351-373	0
105	Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. 2022 , 125-200	0
104	Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. 2022 , 29, 107327482211344	0
103	Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.	0
102	Targeting KRAS in PDAC: A New Way to Cure It?. 2022 , 14, 4982	2
101	Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. 2022 , 45, 450-457	0
100	Brachytherapy via a depot of biopolymer-bound ¹³¹ I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours. 2022 , 6, 1148-1166	1
99	Decision-Making Regarding Perioperative Therapy in Individuals with Localized Pancreatic Adenocarcinoma. 2022 , 36, 961-978	0
98	Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. 2022 , 22,	0
97	Adenosquamous carcinoma of the pancreas: two case reports and review of the literature'. 2022 , 16,	0
96	United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. 2022 , 12, e068010	0
95	Artery encasement on preoperative CT scan does not preclude radical surgery: a case report utilizing sub-adventitial divestment for artery-involving pancreatic cancer.. Publish Ahead of Print,	0

- 94 Management of adenocarcinoma of the pancreatic tail in the elderly. ○
- 93 Impact of Microscopic Confirmation on Therapeutic Management of Pancreatic Cancer Patients: Lessons from an Italian Regional Tumor Registry. **2022**, 14, 5372 ○
- 92 Neoplasms of the Exocrine Pancreas. 1-20 ○
- 91 Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. ○
- 90 Identification of pyroptosis-related gene signature for predicting prognosis of patients with pancreatic cancer using bioinformatics. **2022**, 101, e31043 ○
- 89 Surgeon-Led Clinical Trials in Pancreatic Cancer. **2022**, ○
- 88 Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. **2022**, 34, 100841 ○
- 87 Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence. **2022**, 67, 102305 ○
- 86 A histopathological study of artery wall involvement in pancreatic cancer surgery. ○
- 85 Neoadjuvant therapy impact in early pancreatic cancer: Bioborderline vs. Non-bioborderline **2022**, ○
- 84 S3-Leitlinie zum exokrinen Pankreaskarzinom [Langversion 2.0 [Dezember 2021] AWMF-Registernummer: 032/010OL. **2022**, 60, e812-e909 ○
- 83 Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. **2022**, 100604 ○
- 82 FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: A retrospective observational study. ○
- 81 Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. **2022**, 7, 100605 ○
- 80 A Case Report of New-Onset Diabetes Mellitus as an Early Warning Sign of Pancreatic Ductal Adenocarcinoma in an Elderly Patient: The Earlier the Diagnosis and Surgery, the Better the Prognosis. **2022**, ○
- 79 Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. ○
- 78 Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. 1
- 77 Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. **2022**, 11, 6792 ○

76	Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer?. 2023 , 284, 143-150	0
75	Research Prospect of Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. 2022 , 12, 11459-11464	0
74	Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.	0
73	Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. 2022 , 7,	1
72	Adjuvant and neoadjuvant treatment patterns among resectable pancreatic cancer patients in the USA.	0
71	Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. 2022 , 14, 6179	0
70	Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma [A Swedish nationwide register-based study. 2022	0
69	Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study.	0
68	Diagnostik, Staging und Therapie des Pankreaskarzinoms*. 2022 , 25, 36-45	0
67	Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. 2022 ,	1
66	Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany.	0
65	Correlation between ADC Histogram-Derived Metrics and the Time to Metastases in Resectable Pancreatic Adenocarcinoma. 2022 , 14, 6050	1
64	Enhanced effect of X-rays in the presence of a static magnetic field within a 3d pancreatic cancer model.	0
63	Lessons and open questions in borderline resectable pancreatic cancer. 2022 ,	0
62	Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. 2022 , 8, e12064	0
61	Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.	0
60	Adjuvant Therapy for Pancreatic Adenocarcinoma [Leaving No Rock Unturned.	0
59	Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. 2023 , 12, 465	0

- 58 Vasculitis, CA19-9, and PNI differentially predict response and surgical outcome in pancreatic ductal adenocarcinoma. **2023,** ○
- 57 Pancreatic cancer. **2023,** ○
- 56 Aspirin-Loaded Cross-Linked Lipoic Acid Nanodrug Prevents Postoperative Tumor Recurrence by Residual Cancer Cell Killing and Inflammatory Microenvironment Improvement. ○
- 55 Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models. **2023, 15,** ○
- 54 Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. ○
- 53 Real World Data for Pancreatic Adenocarcinoma from a Population-Based Study in France. **2023, 15, 525** ○
- 52 Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial. **2023, 181, 155-165** ○
- 51 Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial. ○
- 50 Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management. Volume 14, 3589-3598 ○
- 49 Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation. ○
- 48 A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. **2022,** ○
- 47 HROP68: A rare case of medullary pancreatic cancer characterization and chemosensitivity of the first patient-derived cell line. 12, ○
- 46 The NEONAX study. **2023,** ○
- 45 The Current Role of Radiation in Pancreatic Cancer and Future Directions. **2023,** 1
- 44 Extracellular Vesicle-Loaded Oncogenic lncRNA NEAT1 from Adipose-Derived Mesenchymal Stem Cells Confers Gemcitabine Resistance in Pancreatic Cancer via miR-491-5p/Snail/SOCS3 Axis. **2023, 2023, 1-21** ○
- 43 Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. ○
- 42 Hot topics in pancreatic cancer management. 15, 121-126 ○
- 41 Hits and Misses in Novel Pancreatic and Rectal Cancer Treatment Options. **2023, 115, 545-552** ○

- 40 Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma. 15, 677-688 ○
- 39 Pancreatic cancer: Advances and challenges. **2023**, 186, 1729-1754 ○
- 38 Reply to the Letter to the Editor [The Neonax study] by M. W. Böhler and J. Neoptolemos. **2023**, 34, 443-445 ○
- 37 Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT). **2023**, 40, 100603 ○
- 36 Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey. **2023**, 8, 100777 ○
- 35 Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. **2023**, 15, 900 ○
- 34 Hämatologische Neoplasien und solide Tumore. **2022**, 85-151 ○
- 33 Treatment of pancreatic cancer in 2022. **2023**, 1, ○
- 32 Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer. **2023**, 47, 102091 ○
- 31 Research trends and hotspots of neoadjuvant therapy in pancreatic cancer: a bibliometric analysis based on the Web of Science Core Collection. ○
- 30 Cytotoxic Chemotherapy for Pancreatic Adenocarcinoma in England 2010-2017: Survival Outcomes. **2023**, ○
- 29 Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation. 2206004 ○
- 28 Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. **2023**, 4, ○
- 27 Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. **2023**, 23, 266-274 ○
- 26 FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. **2023**, 23, ○
- 25 The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China. **2023**, 13, ○
- 24 Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. **2023**, ○
- 23 Risks and benefits of pancreaticoduodenectomy in patients aged 80 years and over. **2023**, 408, ○

22	Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?. 2023 , 41, 1972-1975	0
21	Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. 2023 , 45, 1914-1949	1
20	Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters. 2023 , 12, 55-61	0
19	Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study.	0
18	Therapeutic drug monitoring of neoadjuvant mFOLFORINOX in resected pancreatic ductal adenocarcinoma. 2023 ,	0
17	Do patients with metastatic pancreatic adenocarcinoma to the lung have improved survival?.	0
16	Neoadjuvant therapy for pancreatic cancer.	0
15	Neoadjuvant chemotherapy for resectable pancreatic cancer: a new standard of care?. 2023 , 28, 80-87	0
14	The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study.	0
13	A population-based nomogram to individualize treatment modality for pancreatic cancer patients underlying surgery. 2023 , 13,	0
12	Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand? A systematic review.	0
11	Utilization of a novel 3D radiologic scoring method to define therapeutic response and surgical candidacy. 2,	0
10	Perineural Invasion of Pancreatic Ductal Adenocarcinoma is Associated with Early Recurrence after Neoadjuvant Therapy Followed by Resection.	0
9	PSMD12 interacts with CDKN3 and facilitates pancreatic cancer progression.	0
8	Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy. 2023 , 15, 2213	0
7	Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study. 2023 , 23,	0
6	Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study. 2023 ,	0
5	Beim Pankreaskarzinom gezielte Ernährung auf keinen Fall vernachlässigen. 2023 , 10, 49-53	0

- 4 Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma. **2022**, 51, 1217-1224
- 3 Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer. **2023**, 15, 2377
- 2 Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. **2022**, 51, 1083-1091
- 1 The application of radiofrequency ablation in pancreatic cancer liver-only recurrence after radical pancreatectomy.